AstraZeneca Divests Entocort GI Drug

Source: Reuters

Jul 09, 2015

AstraZeneca will sell the rights to its gastrointestinal drug Entocort outside the U.S. to Tillotts Pharma.

Switzerland-based Tillotts will pay $215 million in a transation that is expected to complete in the second half of 2015.

AstraZeneca continues to spin off non-core businesses in order to focus on selected therapy areas, such as oncology and diabetes.

Read the Reuters release

Return to the Web Watcher Newsletter  

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments